PF-Atlas › Clinical Trials › NCT02739165

Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis

ART-123 · Phase 3

Registry ID

NCT02739165

Phase

Phase 3

Status

Completed

Drug / intervention

ART-123

Sponsor

Asahi Kasei Therapeutics Corporation

Start

2016-05

About this trial

ART-123 is evaluated in NCT02739165, a Phase 3 idiopathic pulmonary fibrosis study sponsored by Asahi Kasei Therapeutics Corporation. Current status: Completed.

View NCT02739165 on ClinicalTrials.gov →

Explore related

All ART-123 trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT02739165 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.